De-intensification of basal-bolus insulin regimen after initiation of a GLP-1 RA improves glycaemic control and promotes weight loss in subjects with type 2 diabetes

被引：0
|
作者：
Pierpaolo Falcetta
Francesca Nicolì
Fabrizia Citro
Annamaria Ciccarone
Monia Garofolo
Stefano Del Prato
Cristina Bianchi
机构：
[1] University of Pisa,Department of Clinical and Experimental Medicine
[2] University Hospital of Pisa,Department of Medicine
来源：
Acta Diabetologica | 2023年 / 60卷
关键词：
Insulin therapy; Basal-bolus; Glucagon-like peptide-1 receptor agonist; De-intensification;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：53 / 60
页数：7
相关论文
共 50 条
  • [21] Switching from a human insulin basal-bolus regimen to insulin analog basal-bolus therapy with insulin detemir/insulin aspart improves glycemic control and reduces hypoglycemic episodes in patients with type 1 diabetes:: Results from German subgroup of the PREDICTIVE™ study
    Maxeiner, Stephan
    Hansen, Jes B.
    Nauck, Michael
    DIABETES, 2006, 55 : A127 - A127
  • [22] Double-blind mealtime faster-acting insulin aspart vs insulin aspart in basal-bolus improves glycaemic control in Type 1 diabetes: the onset 1 trial
    Russell-Jones, D.
    Bode, B. W.
    De Block, C.
    Franek, E.
    Heller, S.
    Mathieu, C.
    Philis-Tsimikas, A.
    Rose, L.
    Woo, V.
    Osterskov, A. B.
    Graungaard, T.
    Bergenstal, R.
    DIABETIC MEDICINE, 2017, 34 : 8 - 8
  • [23] Comment on "Obesity/Type 2 Diabetes: GLP-1 Agonist Tirzepatide Promotes Weight Loss"
    Blueher, Matthias
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2024, 149 (08) : 415 - 416
  • [24] Faster-acting insulin aspart vs insulin aspart as part of basal-bolus therapy improves postprandial glycaemic control in uncontrolled type 2 diabetes: the onset® 2 trial
    Bowering, K.
    Case, C.
    Harvey, J.
    Reeves, M.
    Sampson, M.
    Strzinek, R.
    Bretler, D. -M.
    Bang, R. B.
    Bode, B. W.
    DIABETOLOGIA, 2016, 59 : S399 - S400
  • [25] Basal-bolus therapy with insulin degludec improves long-term glycaemic control with fewer nocturnal hypoglycaemic events compared with insulin glargine in people with type 2 diabetes
    Hollander, P. A.
    King, A. B.
    Francisco, A. O.
    Endahl, L.
    Garber, A.
    DIABETOLOGIA, 2011, 54 : S421 - S421
  • [26] Insulin degludec improves long-term glycaemic control similarly to insulin glargine but with fewer hypoglycaemic episodes in patients with advanced type 2 diabetes on basal-bolus insulin therapy
    Hollander, P.
    King, A. B.
    Del Prato, S.
    Sreenan, S.
    Balci, M. K.
    Munoz-Torres, M.
    Rosenstock, J.
    Hansen, C. T.
    Niemeyer, M.
    Garber, A. J.
    DIABETES OBESITY & METABOLISM, 2015, 17 (02): : 202 - 206
  • [27] Options for intensification of basal insulin in type 2 diabetes: Premeal insulin or short-acting GLP-1 receptor agonists?
    Darmon, P.
    Raccah, D.
    DIABETES & METABOLISM, 2015, 41 : S21 - S27
  • [28] GLP-1 for six weeks reduces weight and improves insulin sensitivity and glycemic control in patients with type 2 diabetes
    Zander, M
    Madsbad, S
    Holst, JJ
    DIABETES, 2001, 50 : A31 - A31
  • [29] Insulin dose and weight profiles of pre- and post-meal insulin glulisine in a basal-bolus regimen with insulin glargine in patients with Type 1 diabetes
    Klaff, L
    Rosenstock, J
    Garg, S
    Souhami, E
    Ways, K
    DIABETOLOGIA, 2004, 47 : A300 - A300
  • [30] Introduction of insulin glargine to basal-bolus therapy improves metabolic control in patients with type 1 diabetes in everyday clinical practice
    Donaubauer, B
    Schneider, K
    Schweitzer, MA
    DIABETES, 2005, 54 : A518 - A518
12345